Endometrial Cancer

Health-related quality of life data support dostarlimab plus chemotherapy as a standard of care in primary advanced or recurrent endometrial cancer, according to an expert from Copenhagen University Hospital in Denmark.

Dostarlimab produces a survival benefit vs placebo in combination with standard of care therapy regardless of whether patients had mismatch repair deficient/microsatellite instability-high disease.

Drs Eskander and Lewin discuss the sequencing immune checkpoint inhibitors for women with recurrent endometrial cancer.

Sharyn Lewin, MD, FACS, shares how she discusses side effects with patients receiving immune checkpoint inhibitors for advanced/recurrent endometrial cancer.

Data from the phase 3 DUO-E trial indicate that the safety of durvalumab/chemotherapy with or without olaparib/durvalumab or durvalumab monotherapy maintenance in recurrent endometrial cancer was consistent with previous reports of each agent.

Experts explain what they are looking forward to in the future of treatment for patients with ER/PR+ and P53 wild-type or mutated advanced/recurrent endometrial cancer.

The panel discusses their opinions on the use of immunotherapy in different populations of women with advanced/recurrent endometrial cancer.

Prexasertib is currently under investigation as part of a phase 2 trial as a treatment for patients with platinum-resistant ovarian cancer, endometrial adenocarcinoma, and urothelial cancers.

Closing the discussion on advanced endometrial carcinoma, Dr David O’Malley shares his perspective on the future treatment landscape.

The European Medicines Agency validates the potential indication of dostarlimab/chemotherapy in mismatch repair deficient/microsatellite instability–high endometrial cancer based on the phase 3 RUBY trial.

David O’Malley, MD, an expert on advanced endometrial carcinoma, shares additional highlights presented at SGO 2023.

Dostarlimab plus chemotherapy appears to improve progression-free survival vs placebo plus chemotherapy in patients with recurrent endometrial cancer in the phase 3 RUBY trial.

Pembrolizumab plus chemotherapy followed by maintenance pembrolizumab reduced the risk of death or disease progression in patients with mismatch repair proficient or deficient advanced endometrial cancer.

Adavosertib does not appear to be well tolerated in patients with previously treated recurrent or persistent uterine serous carcinoma in the phase 2b ADAGIO trial.

The phase 3 RUBY trial of dostarlimab plus carboplatin and paclitaxel significantly improved progression-free survival in patients with dMMR/MSI-H or MMRp/MSS endometrial cancer.

Patients with advanced endometrial cancer experience early responses to lenvatinib plus pembrolizumab in both patients who were mismatch repair proficient and all-comers.

In the SOLAR phase 1b trial, a clinical benefit was observed when patients with RAS-mutated ovarian or endometrial cancer were given olaparib plus selumetinib.

The lower extremity lymphedema screening questionnaire and gynecological cancer lymphedema questionnaire appear to demonstrate comparable utility in assessing lymphedema in patients with advanced endometrial cancer.

Adding avelumab to carboplatin plus paclitaxel appears to elicit a progression-free survival advantage compared with chemotherapy alone in those with advanced or recurrent endometrial cancer.

Patients with mismatch repair deficient recurrent/advanced endometrial cancer can receive treatment with dostarlimab-gxly following its full approval by the FDA.

ONA-XR plus anastrozole yields preliminary clinical activity in a small population of patients with refractory, hormone receptor (HR)–positive, metastatic endometrial cancer.

Pembrolizumab plus chemotherapy appears to produce a significant improvement in progression-free survival among patients with advanced or recurrent endometrial cancer.

DB-1303, an investigational third generation antibody-drug conjugate that now has FDA fast track designation, may benefit patients with HER2-overexpressing endometrial cancer.

Non-Hispanic Black patients appeared to have higher disease-specific mortality rates than patients of other races, with clinicopathologic factors playing the greatest role in the disparity.

Treatment with dostarlimab plus chemotherapy demonstrated a statistically significant improvement in progression-free survival compared with placebo and chemotherapy among patients with advanced or recurrent endometrial cancer.